-
Something wrong with this record ?
Transurethral resection of bladder cancer with or without fluorescence
J. Horňák, A. Brisuda, M. Babjuk
Language English Country United States
Document type Review, Journal Article
- MeSH
- Cystectomy methods MeSH
- Fluorescence MeSH
- Photosensitizing Agents * MeSH
- Humans MeSH
- Neoplasm Recurrence, Local epidemiology prevention & control pathology MeSH
- Urinary Bladder Neoplasms * pathology MeSH
- Transurethral Resection of Bladder MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
PURPOSE OF REVIEW: Transurethral resection of bladder cancer (TURBT) is in its standard form an inherently imperfect technique. Fluorescence-guided photodynamic diagnosis (PDD) represents one way to improve the outcome by enhancing tumour detection. Fluorescence has been used in connection with bladder cancer since the 1970s, with a number of studies being published since then. However, the method is still not recommended as a standard part of TURBT mainly because of the limited level of evidence of concerned studies, questionable cost-effectiveness and even contradictory results. The review lists the latest articles covering this topic. RECENT FINDINGS: Several recently published meta-analyses reviewed a series of randomized controlled trials (RCTs) concerning PDD assisted TURBT. Results were generally supporting the positive effect on reduction of recurrence rate. However, the mentioned meta-analyses are overlapping in terms of reviewed RCT that provide only a low level of evidence according to a recent Cochrane review. Supposed limitations of PDD (timing of the procedure, low specificity) and possible solutions are also covered. SUMMARY: Most of the published data confirmed reduced early recurrence rate after PDD assisted TURBT comparing to standard TURBT. Its impact on late recurrence rate, progression rate or cost-effectiveness has not been sufficiently demonstrated.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23003978
- 003
- CZ-PrNML
- 005
- 20230425141023.0
- 007
- ta
- 008
- 230418s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/MOU.0000000000001071 $2 doi
- 035 __
- $a (PubMed)36630205
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Horňák, Jakub $u Department of Urology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
- 245 10
- $a Transurethral resection of bladder cancer with or without fluorescence / $c J. Horňák, A. Brisuda, M. Babjuk
- 520 9_
- $a PURPOSE OF REVIEW: Transurethral resection of bladder cancer (TURBT) is in its standard form an inherently imperfect technique. Fluorescence-guided photodynamic diagnosis (PDD) represents one way to improve the outcome by enhancing tumour detection. Fluorescence has been used in connection with bladder cancer since the 1970s, with a number of studies being published since then. However, the method is still not recommended as a standard part of TURBT mainly because of the limited level of evidence of concerned studies, questionable cost-effectiveness and even contradictory results. The review lists the latest articles covering this topic. RECENT FINDINGS: Several recently published meta-analyses reviewed a series of randomized controlled trials (RCTs) concerning PDD assisted TURBT. Results were generally supporting the positive effect on reduction of recurrence rate. However, the mentioned meta-analyses are overlapping in terms of reviewed RCT that provide only a low level of evidence according to a recent Cochrane review. Supposed limitations of PDD (timing of the procedure, low specificity) and possible solutions are also covered. SUMMARY: Most of the published data confirmed reduced early recurrence rate after PDD assisted TURBT comparing to standard TURBT. Its impact on late recurrence rate, progression rate or cost-effectiveness has not been sufficiently demonstrated.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a fotosenzibilizující látky $7 D017319
- 650 _2
- $a fluorescence $7 D005453
- 650 _2
- $a transuretrální resekce močového měchýře $7 D000094463
- 650 12
- $a nádory močového měchýře $x patologie $7 D001749
- 650 _2
- $a cystektomie $x metody $7 D015653
- 650 _2
- $a lokální recidiva nádoru $x epidemiologie $x prevence a kontrola $x patologie $7 D009364
- 655 _2
- $a přehledy $7 D016454
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Brisuda, Antonín
- 700 1_
- $a Babjuk, Marek
- 773 0_
- $w MED00001296 $t Current opinion in urology $x 1473-6586 $g Roč. 33, č. 2 (2023), s. 152-156
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36630205 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425141019 $b ABA008
- 999 __
- $a ok $b bmc $g 1924566 $s 1190187
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 33 $c 2 $d 152-156 $e 20230111 $i 1473-6586 $m Current opinion in urology $n Curr Opin Urol $x MED00001296
- LZP __
- $a Pubmed-20230418